Combined syn sol

1504315282892500
Hospital and Laboratory Support Division
Office of Logistics and Operations (OLAO)
Office of Acquisition and Logistics Management (OALM)

Title: Reagents and consumables for Roche immunostainers

Combined Synopsis Solicitation

COMBINED SYNOPSIS / SOLICITATION WORKFORM

Action Code: Combined Synopsis/Solicitation
Date: October 30, 2026
Classification Code: 6640

NAICS: 325413

Contracting Office Address: 6701 Rockledge Drive, Bethesda, MD 20817 Subject/Title: Reagents and consumables for Roche immunostainers Solicitation Number: 75N98027Q00026
Closing Response Date: November 16, 2026 at 8:00 A.M. Eastern Daylight Time (EDT) Questions Due Date: November 04, 2026 at 8:00 A.M Eastern Daylight Time (EDT) Contact Point(s): Luz Casey, Contract Specialist
Contract Award Type: Firm Fixed Price
Brand Name or Equal Acquisition (FAR 52.211-6): Yes
Place of Contract Performance: Bethesda, MD
Set-aside Status: N/A

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This is intended to be a firm-fixed price contract.

The solicitation number is 75N98027Q00026 and the solicitation is issued as a request for quote (RFQ) for reagents and consumables for Roche immunostainers. The solicitation document, the incorporated provisions, and clauses are those in effect through Federal Acquisition Circular 2024-07, effective August 29, 2024. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. This solicitation is being released unrestricted. The NAICS code is 325413 and the business size standard is 1,250 employees. This requirement is not set aside for small business. This acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13.

OBJECTIVE

The purpose of the proposed acquisition is to issue a new Indefinite Delivery Indefinite Quantity (IDIQ) contract to ensure that the Laboratory of Pathology at the Cancer Center Research (CCR) can continue to purchase stains/reagents and consumables and software upgrades needed to conduct immunohistochemical and in situ hybridization testing for cancer diagnostics and research. These stains/reagents have become an essential part of cancer diagnosis and have an equally important role in the diagnosis of many infectious diseases.